NRx Pharmaceuticals Q1 Earnings Call Highlights
Key takeaways
- NRx Pharmaceuticals Q1 Earnings Call Highlights Market Beat Mon, May 18, 2026 at 8:05 PM GMT+7 8 min read NRXP Key Points Interested in NRx Pharmaceuticals, Inc.?
- NRx said it plans to file an NDA for NRX-100 in Q2, supported by trial data from more than 1,000 patients and real-world evidence from over 65,000 patients.
- The company reported a smaller Q1 net loss of about $1.4 million versus $5.5 million a year earlier, and said it ended the quarter with $6.7 million in cash.
NRx Pharmaceuticals Q1 Earnings Call Highlights Market Beat Mon, May 18, 2026 at 8:05 PM GMT+7 8 min read NRXP Key Points Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better.
KETAFREE moved closer to a potential summer 2026 approval after the FDA issued mostly minor review comments, and NRx said it has already begun commercial manufacturing at scale. Management believes the product could serve both hospital and ketamine clinic markets, where supply shortages persist.
NRx said it plans to file an NDA for NRX-100 in Q2, supported by trial data from more than 1,000 patients and real-world evidence from over 65,000 patients. The FDA also indicated it may consider approval based on existing data and broader depression indications, with priority review pathways available.